The role of IL-17 inhibitors in the treatment of reactive arthritis

Abstract

o study the relationship between the IL-17A gene G197A polymorphism and the presence of resistance to secukinumab in patients with reactive arthritis with spondyloarthritis. Material and methods: The study was conducted in the rheumatology department of the Tashkent City Clinical Hospital №3. The study included 76 patients (73 women, 3 men aged 24-65 years) with reactive arthritis with spondyloarthritis. The control group consisted of 24 healthy volunteers without a burdened rheumatological history. Results: All patients received basic therapy with the IL-17A inhibitor secukinumab (at a dose of 150 mg subcu- taneously) for 6 months. In patients with reactive arthritis, significant differences in the distribution of the alleles of the IL-17A gene G197A polymorphism were found. When com- paring genotypic variants, it was found that the healthy GG and mutant AA genotypes were more common in patients, and the heterozygous GA genotype was more common in healthy patients. Conclusions: The G197A polymorphism of the IL-17A gene is associated with the presence of resis- tance to secukinumab and disease activity.